FilingReader Intelligence
Amoytop Biotech reports 27% revenue growth in H1
August 20, 2025 at 05:13 PM UTC•By FilingReader AI
Xiamen Amoytop Biotech reported 26.96% revenue growth and 40.60% rise in net profit for H1 2025, driven by increased patient adoption of Pegbin. Operating cash flow surged 397.97%.
The company achieved approval of YPEGGH Injection and made progress in clinical trials. Amoytop invested in Xiamen Zhimou Investment and Beijing Anmuduo Kang Internal Medicine Clinic to expand offerings.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
SSE:688278•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Xiamen Amoytop Biotech publishes news
Free account required • Unsubscribe anytime